Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
A centralised kitchen which provides 5,000 breakfast meals per day is to be started at Perumallapuram, Kakinada, Andhra Pradesh
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
It recognizes the company's commitment to safeguarding sensitive data, protecting patient information
Subscribe To Our Newsletter & Stay Updated
